GlassScriptPhysician profile
Gurpreet Bambra
NPI 1649428475
$13,158.84
in general payments reported to CMS, 2019-2025
27 companies · $7,452 in 2025
The $7,452 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,388 · 2020: $335 · 2021: $403 · 2022: $866 · 2023: $1,591 · 2024: $1,125 · 2025: $7,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $5,600 · Food and Beverage: $3,567 · Travel and Lodging: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $5,599.99 |
| Food and Beverage | $3,566.86 |
| Travel and Lodging | $1,000.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,657.02 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $2,238.05 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $840.64 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Genentech USA, INC. | $397.78 | 2019-2024 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $387.35 | 2019-2024 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $319.65 | 2023-2025 | Dupixent |
| Insmed, INC. | $313.44 | 2022-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $283.46 | 2022-2025 | |
| Electromed, INC. | $238.26 | 2022-2024 | Smartvest |
| Mallinckrodt Hospital Products INC. | $199.48 | 2023-2024 | Acthar |
| Mylan Specialty L.P. | $181.61 | 2023-2024 | Yupelri |
| Philips North America LLC | $122.42 | 2019-2023 | |
| Amgen INC. | $119.70 | 2022-2025 | Tezspire, Tavneos |
| Allergan, INC. | $112.17 | 2019 | |
| Sunovion Pharmaceuticals INC. | $97.85 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Grifols USA, LLC | $87.45 | 2019-2025 | Prolastin-C Liquid |
| Baxter Healthcare | $82.40 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Takeda Pharmaceuticals U.S.A., INC. | $81.67 | 2020-2023 | Glassia |
| Shire North American Group INC | $69.57 | 2019 | |
| Novartis Pharmaceuticals Corporation | $50.87 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $41.10 | 2024 | Zerbaxa, Dificid, Recarbrio |
| Actelion Pharmaceuticals US, INC. | $36.67 | 2019-2023 | Uptravi, Opsumit |
| Tactile Systems Technology INC | $32.51 | 2025 | Nimbl, Flexitouch Plus |
| Circassia INC. | $25.67 | 2019 | |
| Beckman Coulter, INC. | $24.96 | 2024 | Dxh 900 Hematology System |
| Abbvie INC. | $20.59 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gurpreet Bambra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.